Skip to main content
Fig. 5 | Lipids in Health and Disease

Fig. 5

From: Lipid alterations play a role in the integration of PD-1/PD-L1 inhibitors and anlotinib for the treatment of advanced non–small-cell lung cancer

Fig. 5

Detecting significant variations in the constituents of PG among three patient groups. A The PG levels in the PR group did not show any significant alteration. B There was a significant increase in PG 36:1 levels in the SD group after treatment. C PG 36:0 and PG 36:1 levels showed a significant increase in the PD group after treatment. To compare the alterations in PG levels before and after treatment, a paired two-tailed Student’s t-test was conducted within each group (PR, SD, PD). The comparison was made between the non-treatment group and the group treated with a combination of anlotinib and a PD-1 inhibitor. A P -value of less than 0.05 was considered statistically significant and marked with an asterisk

Back to article page

Lipids in Health and Disease

ISSN: 1476-511X